Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness

Autor: E Oropeza, S Seker, S Carrel, A Mazumder, A Jimenez, SN VandenHeuvel, DA Noltensmeyer, NB Punturi, JT Lei, B Lim, S Raghavan, MN Bainbridge, S Haricharan

Cell cycle checkpoint kinases activated by DNA repair pathways, ATM/Chk2 and ATR/Chk1 are important tumor suppressors. Germline mutations in these genes associate with increased cancer incidence. Specifically, ATM and CHEK2 germline variants associat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e9888a8accbacc78cdf3c3ed6356816b
https://doi.org/10.1101/2020.10.29.361352

Construction of an Ohmic Contact Cathode by Two Metal Sulfides for efficient Capture and Catalysis of Polysulfide.

Autor: Chen JZ; State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, 100029, P. R. China.; Key Laboratory of Carbon Fiber and Functional Polymers (Beijing University of Chemical Technology), Ministry of Education, Beijing, 100029, P. R. China., Hou YL; State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, 100029, P. R. China.; Key Laboratory of Carbon Fiber and Functional Polymers (Beijing University of Chemical Technology), Ministry of Education, Beijing, 100029, P. R. China., Zhang BH; State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, 100029, P. R. China.; Key Laboratory of Carbon Fiber and Functional Polymers (Beijing University of Chemical Technology), Ministry of Education, Beijing, 100029, P. R. China., Chen PP; State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, 100029, P. R. China.; Key Laboratory of Carbon Fiber and Functional Polymers (Beijing University of Chemical Technology), Ministry of Education, Beijing, 100029, P. R. China., Lei JT; State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, 100029, P. R. China.; Key Laboratory of Carbon Fiber and Functional Polymers (Beijing University of Chemical Technology), Ministry of Education, Beijing, 100029, P. R. China., Li ZA; State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, 100029, P. R. China.; Key Laboratory of Carbon Fiber and Functional Polymers (Beijing University of Chemical Technology), Ministry of Education, Beijing, 100029, P. R. China., Zhao DL; State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing, 100029, P. R. China.; Key Laboratory of Carbon Fiber and Functional Polymers (Beijing University of Chemical Technology), Ministry of Education, Beijing, 100029, P. R. China.

Publikováno v: Small (Weinheim an der Bergstrasse, Germany) [Small] 2024 Nov; Vol. 20 (44), pp. e2403871. Date of Electronic Publication: 2024 Jul 14.

PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.

Autor: Chen A; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Integrative Molecular and Biomedical Sciences Program, Baylor College of Medicine, Houston, Texas.; Repare Therapeutics, Cambridge, Massachusetts., Kim BJ; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas., Mitra A; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., Vollert CT; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Employee of Adrienne Helis Malvin Medical Research Foundation, New Orleans, Louisiana., Lei JT; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Department of Human and Molecular Genetics, Baylor College of Medicine, Houston, Texas., Fandino D; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., Anurag M; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Holt MV; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., Gou X; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., Pilcher JB; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., Goetz MP; Department of Oncology, Mayo Clinic, Rochester, Minnesota., Northfelt DW; Division of Hematology and Medical Oncology at Mayo Clinic, Phoenix, Arizona., Hilsenbeck SG; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Marshall CG; Repare Therapeutics, Cambridge, Massachusetts., Hyer ML; Repare Therapeutics, Cambridge, Massachusetts., Papp R; Repare Therapeutics, Saint-Laurent, Quebec, Canada., Yin SY; Repare Therapeutics, Saint-Laurent, Quebec, Canada., De Angelis C; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy., Schiff R; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Fuqua SAW; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Ma CX; Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri., Foulds CE; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Ellis MJ; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2024 Oct 01; Vol. 23 (10), pp. 1494-1510.

Pan-cancer proteogenomics expands the landscape of therapeutic targets.

Autor: Savage SR; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA., Yi X; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA., Lei JT; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA., Wen B; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA., Zhao H; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital and Key Laboratory of Carcinogenesis and Cancer Invasion of the Ministry of China, Fudan University, 180 Fenglin Road, Shanghai 200032, China., Liao Y; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA., Jaehnig EJ; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA., Somes LK; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA., Shafer PW; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA., Lee TD; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA., Fu Z; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital and Key Laboratory of Carcinogenesis and Cancer Invasion of the Ministry of China, Fudan University, 180 Fenglin Road, Shanghai 200032, China., Dou Y; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA., Shi Z; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA., Gao D; Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China., Hoyos V; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA., Gao Q; Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital and Key Laboratory of Carcinogenesis and Cancer Invasion of the Ministry of China, Fudan University, 180 Fenglin Road, Shanghai 200032, China. Electronic address: gao.qiang@zs-hospital.sh.cn., Zhang B; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: bing.zhang@bcm.edu.

Publikováno v: Cell [Cell] 2024 Aug 08; Vol. 187 (16), pp. 4389-4407.e15. Date of Electronic Publication: 2024 Jun 24.

Isobavachalcone, a natural sirtuin 2 inhibitor, exhibits anti-triple-negative breast cancer efficacy in vitro and in vivo.

Autor: Ren YL; State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China., Lei JT; State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China., Zhang TR; State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China., Lu P; State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China., Cui DD; State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China., Yang B; West China School of Pharmacy, Sichuan University, Chengdu, China.; Department of Pharmacy, The Seventh People's Hospital of Chengdu, Chengdu, China.; Department of Pharmacy, Panzhihua Central Hospital, Dali University, Panzhihua, China., Zhao GY; State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China., Peng F; West China School of Pharmacy, Sichuan University, Chengdu, China., Cao ZX; State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China., Peng C; State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China., Li YZ; State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

Publikováno v: Phytotherapy research : PTR [Phytother Res] 2024 Apr; Vol. 38 (4), pp. 1815-1829. Date of Electronic Publication: 2024 Feb 13.